ASCA: Genetic marker, predictor of disease, or marker of a response to an environmental antigen?

Gut

Volumn 54, Issue 9, 2005, Pages 1212-1213

  Seibold, F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN;

AUTOIMMUNE DISEASE; CELIAC DISEASE; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; GASTROSCOPY; GENETIC MARKER; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER DISEASE; NOTE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SEROLOGY; ULCERATIVE COLITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; BIOLOGICAL MARKERS; CROHN DISEASE; CROSS REACTIONS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 23944492085     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.065227     Document Type: Note

References (15)

1. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
2. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7.
3. Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992;33:657-62.
4. Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 1992;33:1071-5.
5. Shanahan F, Duerr R, Rotter J, et al. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992;103:456-61.
6. Seibold F, Slametschka D, Gregor M, et al. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532-6.
7. Lee C, Lennard-Jones J, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995;108:428-33.
8. Sendid B, Quinton J, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93:1306-10.
9. Seibold F, Stich O, Hufnagl R, et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001;36:196-201.
10. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8-15.
11. Seibold F, Brandwein S, Simpson S, et al. pANCA represent a crossreactivity to enteric bacterial antigens. J Clin Immunol 1998;18:153-60.
12. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6.
13. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
14. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363:1544-6.
15. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the MBL are associated with immune reactivity to Saccharomyces cerevisiae in Crohn's disease. Gastroenterology 2004;127:1076-84.